Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

CellCentric’s Director of Cancer Biology talks inobrodib’s mechanism of action in the context of latest efficacy and safety data, treating late/last stage multiple myeloma

Tolerability and clinical activity of novel first in class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/ refractory multiple myeloma

Potent preclinical activity of the EP300/CBP bromodomain
inhibitor CCS1477/inobrodib in multiple myeloma

An open-label phase I/IIa study to evaluate the safety and efficacy of inobrodib
(CCS1477) as monotherapy in patients with relapsed/refractory multiple myeloma

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of the p300/CBP bromodomains, as monotherapy and in combination, in patients with advanced haematological malignancies

Views from key opinion leaders and a clinical trial patient on recent positive inobrodib results in relapsed refractory multiple myeloma

Potent pre-clinical and early phase clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma

Therapeutic Targeting of EP300/CBP by Bromodomain Inhibition in Acute Myeloid Leukemia

p300/CBP bromodomain inhibitor CCS1477 enhances the efficacy of immune checkpoint blockade therapy in cancer treatment

CCS1477, a novel p300/CBP bromodomain inhibitor, enhances efficacy of azacitidine and venetoclax in pre-clinical models of acute myeloid leukaemia and lymphoma